Creating new antibiotics to fight resistant bacteria
Discovery through chemical synthesis of antibiotics effective against modern bacterial pathogens
This study is working on creating new antibiotics to help people who have infections caused by tough bacteria that don't respond to current treatments, so patients can have better options for getting better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11015000 on NIH RePORTER |
What this research studies
This research focuses on developing new antibiotics specifically designed to combat modern bacterial pathogens that have become resistant to existing treatments. The team will synthesize a variety of lincosamide antibiotics, a class that has not seen new entries in over 50 years, to address the urgent threat posed by multi-drug resistant bacteria. By creating novel compounds through efficient synthetic pathways, the research aims to provide effective treatment options for infections caused by these resistant strains. Patients may benefit from new therapies that are more effective against infections that are currently difficult to treat.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by multi-drug resistant bacteria, particularly those involving Acinetobacter baumannii and other ESKAPE pathogens.
Not a fit: Patients with infections caused by bacteria that are not resistant to current antibiotics may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing new antibiotics through similar synthetic approaches, indicating a potential for success in this area.
Where this research is happening
Cambridge, United States
- Harvard University — Cambridge, United States (Active)
Researchers
- Principal investigator: Myers, Andrew G — Harvard University
- Study coordinator: Myers, Andrew G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.